首页> 美国卫生研究院文献>Clinical Kidney Journal >The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary
【2h】

The European Renal Association – European Dialysis and Transplant Association Registry Annual Report 2014: a summary

机译:欧洲肾脏协会–欧洲透析和移植协会注册管理机构2014年年度报告:摘要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

>Background: This article summarizes the European Renal Association – European Dialysis and Transplant Association Registry’s 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2014 within 35 countries. >Methods: In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51 national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated patient level data. The incidence, prevalence and survival probabilities of these patients were determined. >Results: In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31 December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp. This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014, 19 406 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied considerably throughout Europe. For patients commencing RRT during 2005–09, the 5-year-adjusted patient survival probabilities on all RRT modalities was 63.3% (95% confidence interval 63.0–63.6). The expected remaining lifetime of a 20- to 24-year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD.
机译:>背景:本文总结了欧洲肾脏协会–欧洲透析和移植协会注册处2014年年度报告。它描述了2014年在35个国家/地区针对终末期肾病(ESRD)的肾脏替代疗法(RRT)的流行病学。 >方法:在2016年,ERA-EDTA注册中心收到了来自51个国家或地区肾脏注册机构2014年接受ESRT RRT治疗的患者的数据。 32个注册表提供了单独的患者水平数据,还有19个提供了汇总的患者水平数据。确定了这些患者的发病率,患病率和生存率。 >结果:2014年,有70953名个体开始了ESRD的RRT治疗,相当于未经调整的总发病率是每百万人口133(pmp)。发病率是十倍。从乌克兰的23 pmp到葡萄牙的237 pmp。在开始RRT的患者中,近三分之二是男性,超过一半的年龄≥65岁,四分之一的患者以糖尿病为主要肾脏诊断。到开始RRT的第91天,已有81%的患者接受了血液透析。 2014年12月31日,有490743个人接受了ESRD的RRT治疗,这等于未经调整的924 pmp患病率。在整个欧洲范围内变化幅度超过十倍,从乌克兰的157 pmp到葡萄牙的1794 pmp。 2014年,进行了19406例肾脏移植,相当于未经调整的总体移植率为36 pmp。在整个欧洲,情况再次大不相同。对于2005–09年开始接受RRT的患者,所有RRT方式下经过5年调整的患者生存率均为63.3%(95%置信区间为63.0–63.6)。接受透析或肾脏移植的20至24岁ESRD患者的预期剩余寿命分别为21.9年和44.0年。这大大低于没有ESRD的20岁患者的预期剩余寿命61.8年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号